Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).

Autores de IIS La Fe

• 

  María Ángeles Tormo Mas

  Autor

• Noelia Alonso Lázaro

  Autor

• Pau Montesinos Fernández

  Autor

• Maria Josefa Moreno Monedero

  Autor

Participantes ajenos a IIS La Fe

• Ribera JM
• García O
• Grande C
• Esteve J
• Oriol A
• Bergua J
• González-Campos J
• Vall-Llovera F
• Hernández-Rivas JM
• García D
• Brunet S
• Barba P
• Miralles P
• Llorente A
• Hernández-Rivas JÁ
• Bernal T

Grupos

• Hematología y Hemoterapia

Abstract

The use of rituximab together with intensive chemotherapy in Burkitt's lymphoma or leukemia (BL) has been scarcely explored. This study prospectively evaluated and compared the outcome and toxicity of human immunodeficiency virus (HIV)-positive and HIV-negative patients with BL who were treated in an intensive immunochemotherapy-based and age-adapted trial.